Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $114.0 million.

  • OptimizeRx's Non-Current Assets fell 349.69% to $114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year increase of 29146.04%. This contributed to the annual value of $117.2 million for FY2024, which is 907.49% down from last year.
  • Latest data reveals that OptimizeRx reported Non-Current Assets of $114.0 million as of Q3 2025, which was down 349.69% from $115.2 million recorded in Q2 2025.
  • OptimizeRx's 5-year Non-Current Assets high stood at $128.9 million for Q4 2023, and its period low was $25.4 million during Q1 2022.
  • For the 5-year period, OptimizeRx's Non-Current Assets averaged around $69.1 million, with its median value being $36.5 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 25729.9% in 2023, then tumbled by 923.33% in 2025.
  • Over the past 5 years, OptimizeRx's Non-Current Assets (Quarter) stood at $25.9 million in 2021, then soared by 39.43% to $36.1 million in 2022, then soared by 257.3% to $128.9 million in 2023, then dropped by 9.07% to $117.2 million in 2024, then dropped by 2.73% to $114.0 million in 2025.
  • Its Non-Current Assets was $114.0 million in Q3 2025, compared to $115.2 million in Q2 2025 and $116.1 million in Q1 2025.